Список литературы к Главе 16

1. da Cunha­Bang C. et al. Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo­immunotherapy: a Danish population­based study of 10 455 patients // Blood Cancer J. 2016. Vol. 6, N 11. P. e499.

2. Perkins J.G. et al. Frequency and type of serious infections in fludarabine­refractory B­cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population // Cancer. 2002. Vol. 94, N 7. P. 2033–2039.

3. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia et al. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial // N. Engl. J. Med. 1988. Vol. 319, N 14. P. 902–907.

4. Andersen M.A. et al. Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish Nationwide Cohort Study // Haematologica. 2018. Vol. 103, N 7. P. e300–e303.

5. Wadhwa P.D., Morrison V.A. Infectious complications of chronic lymphocytic leukemia // Semin. Oncol. 2006. Vol. 33, N 2. P. 240–249.

6. Crassini K.R. et al. Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment­free and overall survival in chronic lymphocytic leukaemia // Br. J. Haematol. 2018. Vol. 181, N 1. P. 97–101.

7. Moreira J. et al. Infectious complications among individuals with clinical monoclonal B­cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls // Leukemia. 2013. Vol. 27, N 1. P. 136–141.

18. Cutucache C.E. Tumor­induced host immunosuppression: special focus on CLL // Int. Immunopharmacol. 2013. Vol. 17, N 1. P. 35–41.

19. Gonzalez­Rodriguez A.P. et al. Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia // Leuk. Lymphoma. 2010. Vol. 51, N 10. P. 1829–1836.

20. Jadidi­Niaragh F. et al. Increased frequency of CD8+ and CD4+ regulatory T cells in chronic lymphocytic leukemia: association with disease progression // Cancer Invest. 2013. Vol. 31, N 2. P. 121–131.

21. Burger J.A. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia // Hematology Am. Soc. Hematol. Educ. Program. 2011. Vol. 2011. P. 96–103.

22. Fayad L. et al. Interleukin­6 and interleukin­10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome // Blood. 2001. Vol. 97, N 1. P. 256–263.

23. Lotz M., Ranheim E., Kipps T.J. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells // J. Exp. Med. 1994. Vol. 179, N 3. P. 999–1004.

24. Schlesinger M., Broman I., Lugassy G. The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives // Leukemia. 1996. Vol. 10, N 9. P. 1509–1513.

25. Morrison V.A., Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches // Best Pract. Res. Clin. Haematol. 2010. Vol. 23, N 1. P. 145–153.

26. Itala M., Vainio O., Remes K. Functional abnormalities in granulocytes predict susceptibility to bacterial infections in chronic lymphocytic leukaemia // Eur. J. Haematol. 1996. Vol. 57, N 1. P. 46–53.

27. Zeya H.I. et al. Monocyte and granulocyte defect in chronic lymphocytic leukemia // Am. J. Pathol. 1979. Vol. 95, N 1. P. 43–54.

28. Tadmor T., Welslau M., Hus I. A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia // Expert Rev. Hematol. 2018. Vol. 11, N 1. P. 57–70.

29. Itala M. et al. Infections and serum IgG levels in patients with chronic lymphocytic leukemia // Eur. J. Haematol. 1992. Vol. 48, N 5. P. 266-270.

30. Molica S., Levato D., Levato L. Infections in chronic lymphocytic leukemia. Analysis of incidence as a function of length of follow­up // Haematologica. 1993. Vol. 78, N 6. P. 374–377.

31. Svensson T., Hoglund M., Cherif H. Clinical significance of serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukemia // Scand. J. Infect. Dis. 2013. Vol. 45, N 7. P. 537–542.

32. Andersen M.A. et al. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death // Leuk. Lymphoma. 2016. Vol. 57, N 7. P. 1592–1599.

33. Freeman J.A. et al. Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia // Leuk. Lymphoma. 2013. Vol. 54, N 1. P. 99–104.

34. Aittoniemi J. et al. Opsonising immunoglobulins and mannan­binding lectin in chronic lymphocytic leukemia // Leuk. Lymphoma. 1999. Vol. 34, N 3–4. P. 381–385.

35. Hensel M. et al. Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia // Br. J. Haematol. 2003. Vol. 122, N 4. P. 600–606.

36. Francis S. et al. The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia // Cancer. 2006. Vol. 107, N 5. P. 1023–1033.

37. Sinisalo M. et al. Similar humoral immunity parameters in chronic lymphocytic leukemia patients independent of VH gene mutation status // Leuk. Lymphoma. 2004. Vol. 45, N 12. P. 2451–2454.

38. Dmitrieva E.A., Nikitin E.A., Markova E.E., Dmitrieva N.Yu., Ptushkin V.V. Infections in chronic lymphocytic leukemia patients treated with ibrutinib: incidence and predisposing factors // Clin. Oncohematol. 2019. Vol. 12. P. 438–448.

39. Paul M. et al. Systematic review and meta­analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis // Antimicrob. Agents Chemother. 2010. Vol. 54, N 11. P. 4851–4863.

40. Andersen M.A. et al. Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation­wide cohort study // Leukemia. 2019. Vol. 33, N 3. P. 662–670.

41. Wardill H.R., Bowen J.M. Chemotherapy­induced mucosal barrier dysfunction: an updated review on the role of intestinal tight junctions // Curr. Opin. Support. Palliat. Care. 2013. Vol. 7, N 2. P. 155–161.

42. Wong A. et al. Increased risk of invasive pneumococcal disease in haematological and solid­organ malignancies // Epidemiol. Infect. 2010. Vol. 138, N 12. P. 1804–1810.

43. Lipsky B.A. et al. Risk factors for acquiring pneumococcal infections // Arch. Intern. Med. 1986. Vol. 146, N 11. P. 2179–2185.

44. Kjellander C. et al. Bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal single­center study // Ann. Hematol. 2016. Vol. 95, N 6. P. 871–879.

45. Travade P. et al. [Severe infections associated with chronic lymphoid leukemia. 159 infectious episodes in 60 patients] // Presse Med. 1986. Vol. 15, N 34. P. 1715–1718.

46. Korona­Glowniak I. et al. Bacterial colonization in patients with chronic lymphocytic leukemia and factors associated with infections and colonization // J. Clin. Med. 2019. Vol. 8, N 6. P. 861.

47. Shadrivova O. et al. Invasive Aspergillosis and mucormycosis in oncohematological patients // Oncohematology. 2018. Vol. 13. P. 39–47.

48. Popova M.O. et al. [Invasive mycoses during hematopoietic stem cell transplantation] // Ter. Arkh. 2012. Vol. 84, N 7. P. 50–57.

49. Pagano L., Facchinelli D. Invasive fungal infections in patients with chronic lymphoproliferative disorders in the era of target drugs // Mediterr. J. Hematol. Infect. Dis. 2018. Vol. 10. Article ID e2018063.

50. Nosari A.M. et al. Invasive fungal infections in lymphoproliferative disorders: a monocentric retrospective experience // Leuk. Lymphoma. 2014. Vol. 55, N 8. P. 1844–1848.

51. Visentin A. et al. Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia // Hematol. Oncol. 2017. Vol. 35, N 4. P. 925–928.

52. Pagano L. et al. Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations // Blood Rev. 2017. Vol. 31, N 2. P. 17–29.

53. Laros­van Gorkom B.A. et al. Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands // Neth. J. Med. 2007. Vol. 65, N 9. P. 333–338.

54. Rai K.R. et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine // J. Clin. Oncol. 2002. Vol. 20, N 18. P. 3891–3897.

55. Wijermans P.W., Gerrits W.B., Haak H.L. Severe immunodeficiency in patients treated with fludarabine monophosphate // Eur. J. Haematol. 1993. Vol. 50, N 5. P. 292–296.

56. Langerbeins P. et al. The CLL12 trial protocol: a placebo­controlled double­blind phase III study of ibrutinib in the treatment of early­stage chronic lymphocytic leukemia patients with risk of early disease progression // Future Oncol. 2015. Vol. 11, N 13. P. 1895–1903.

57. Chamilos G., Lionakis M.S., Kontoyiannis D.P. Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways // Clin. Infect. Dis. 2018. Vol. 66, N 1. P. 140–148.

58. Ahn I.E. et al. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single­agent ibrutinib // Blood. 2016. Vol. 128, N 15. P. 1940–1943.

59. O’Brien S. et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE­17): a phase 2, open­label, multicentre study // Lancet Oncol. 2016. Vol. 17, N 10. P. 1409–1418.

60. Sun C. et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib // Blood. 2015. Vol. 126, N 19. P. 2213–2219.

61. Barr P.M. et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL // Blood. 2017. Vol. 129, N 19. P. 2612–2615.

62. Lionakis M.S. et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma // Cancer Cell. 2017. Vol. 31, N 6. P. 833–843.e5.

63. Rogers K.A. et al. incidence and type of opportunistic infections during ibrutinib treatment at a single academic center // Blood. 2017. Vol. 130, suppl. 1. P. 830–830.

64. Varughese T. et al. Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer // Clin. Infect. Dis. 2018. Vol. 67, N 5. P. 687–692.

65. Herbst S. et al. Phagocytosis­dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co­ordinates innate immunity to Aspergillus fumigatus // EMBO Mol. Med. 2015. Vol. 7, N 3. P. 240–258.

66. Bercusson A. et al. Ibrutinib blocks Btk­dependent NF­ĸB and NFAT responses in human macro­ phages during Aspergillus fumigatus phagocytosis // Blood. 2018. Vol. 132, N 18. P. 1985–1988.

67. Dubovsky J.A. et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1­selective pressure in T lymphocytes // Blood. 2013. Vol. 122, N 15. P. 2539–2549.

68. Maffei R. et al. Immunomodulatory effect of ibrutinib: reducing the barrier against fungal infections // Blood Rev. 2020. Vol. 40. Article ID 100635.

69. Ullmann A.J. et al. Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016 // Ann. Hematol. 2016. Vol. 95, N 9. P. 1435–1455.

70. Maschmeyer G. et al. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL) // Leukemia. 2019. Vol. 33, N 4. P. 844–862.